172 related articles for article (PubMed ID: 12209742)
1. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
Hotte SJ; Winquist EW; Stitt L; Wilson SM; Chambers AF
Cancer; 2002 Aug; 95(3):506-12. PubMed ID: 12209742
[TBL] [Abstract][Full Text] [Related]
2. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
[TBL] [Abstract][Full Text] [Related]
4. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.
Garcia JA; Rosenberg JE; Weinberg V; Scott J; Frohlich M; Park JW; Small EJ
BJU Int; 2007 Mar; 99(3):519-24. PubMed ID: 17407512
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
9. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
10. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma.
Wong TS; Kwong DL; Sham J; Wei WI; Kwong YL; Yuen AP
Eur J Surg Oncol; 2005 Jun; 31(5):555-8. PubMed ID: 15922893
[TBL] [Abstract][Full Text] [Related]
11. [Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma].
Cui BK; Zhang CQ; Zhang Y; Yuan YF; Zhang YQ; Shi M; Chen MS; Li SP; Li JQ
Ai Zheng; 2006 Jul; 25(7):876-9. PubMed ID: 16831281
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
Martinetti A; Bajetta E; Ferrari L; Zilembo N; Seregni E; Del Vecchio M; Longarini R; La Torre I; Toffolatti L; Paleari D; Bombardieri E
Endocr Relat Cancer; 2004 Dec; 11(4):771-9. PubMed ID: 15613451
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina.
Minoretti P; Falcone C; Calcagnino M; Emanuele E; Buzzi MP; Coen E; Geroldi D
Eur Heart J; 2006 Apr; 27(7):802-7. PubMed ID: 16421174
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
16. Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy.
Snitcovsky I; Leitão GM; Pasini FS; Brunialti KC; Mangone FR; Maistro S; de Castro G; Villar RC; Federico MH
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):807-11. PubMed ID: 19687403
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
Humphrey PA; Halabi S; Picus J; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
Clin Genitourin Cancer; 2006 Mar; 4(4):269-74. PubMed ID: 16729910
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
[TBL] [Abstract][Full Text] [Related]
20. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
